Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

381 recalls, newest first

Class II · Moderate risk

Tadalafil USP

CGMP Deviations:Noted during FDA inspection

Ongoing cGMP deviation Shoolin Pharma Chem LLP NDC 85702-002-02 D-0760-2026
Class II · Moderate risk

Sildenafil Citrate USP

CGMP Deviations:Noted during FDA inspection

Ongoing cGMP deviation Shoolin Pharma Chem LLP NDC 85702-001-05 D-0759-2026
Class II · Moderate risk

Azelaic Acid Gel

CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were received.

Ongoing cGMP deviation Glenmark Pharmaceuticals Inc., USA NDC 68462-626-52 D-0731-2026
Class II · Moderate risk

Synjardy XR Tablets

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

Ongoing cGMP deviation Boehringer Ingelheim Pharmaceuticals, Inc. D-0657-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0642-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0641-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0640-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0639-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0638-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0637-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0636-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0635-2026
Class II · Moderate risk

Cura Hongos

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0634-2026
Class II · Moderate risk

Rapidol

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0633-2026
Class II · Moderate risk

Lil Drug Store

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0632-2026
Class II · Moderate risk

Circle K

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0631-2026
Class II · Moderate risk

Lucky Super Soft

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0630-2026
Class II · Moderate risk

Lucky Super Soft

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0629-2026
Class II · Moderate risk

Revitaderm Wound Care

CGMP Deviations; product manufactured in the same facility under the same conditions as the product found to be contaminated

Ongoing cGMP deviation Blaine Labs Inc NDC 63347-120-02 D-0699-2026

Recalls by year